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Introduction
p53 was discovered 25 years ago as a mammalian
protein that was targeted for disruption by tumor virus
proteins such as SV40 and frequently overexpressed 
(in a defective form) in human tumors [1-3]. Since then,
research of p53 activities has been reported in more than
3000 journal articles per year. The astounding amount of
research conducted on p53 stems from its frequent
mutation in human cancers (approximately 50% overall-
more than any other single gene) and from its broad
spectrum of activities. Besides mutation, inactivation of
the p53 pathway occurs by defects in “upstream” activa-
tion of p53 or in its “downsteam” effector proteins, broad-
ening p53’s relevance to nearly all human cancers. The
p53 protein acts as a transcription factor to induce target
genes involved in cell cycle checkpoints, DNA repair, cell
death, and cell senescence, particularly in response to
DNA damage [4]. As “guardian of the genome”, p53 is
responsible for ensuring that DNA repair proteins have
the opportunity to repair damaged DNA sequence in
cells under stress. In the skin these stresses include
sunlight damage, drugs applied topically or systemically,
even wounding or other physiological inducers of cell
division and DNA conformational changes [4]. p53 is
frequently targeted for dermatological treatments. For
example, psoriasis treatment by psoralin-UV-A (PUVA)
induces intended genotoxic damage, activating p53; but
DNA damage may also have the negative result of induc-
ing p53 mutation, possibly leading to squamous cell
carcinoma (SCC) [5]. Introducing wild type p53 back into
a variety of human cancer cell lines stops their growth or
induces apoptosis (programmed cell death). It is thought 
that therapies that stabilize mutant p53 in a wild type
conformation or reintroduce wild type p53 into tumor
cells will be therapeutic for a broad range of human
cancers [6-8].
The two other members of the p53 family, p63 and
p73, were discovered in 1997 and classified in relation to
p53 based on their structural similarity [9, 10]. p53, p63
and p73 each have their own unique functions in
genome maintenance and embryonic development in
addition to performing similar functions such as inducing
common downstream target genes for cell cycle arrest
and apoptosis in response to DNA damage. The p53,
p63 and p73 genes give rise to multiple mRNA and
protein isoforms (forms with distinct amino acid
sequences and activities). While they are approximately
65% identical in the central DNA binding domain [11],
they differ appreciably at their N terminal transactivating
domains (TA) and C terminal oligomerization/isomeriza-
tion domains (ISO). These different isoforms make use
of separate promoters (start sites for mRNA transcrip-
tion) to produce transcriptionally active (TA) isoforms
and dominant negative (∆N) isoforms that lack an N
terminal transcriptional activation domain [12]. Wild type
p63 and p73 isoforms can oligomerize with each other
and with mutant p53 [13], establishing coregulatory inter-
actions between family members. Clearly, the gene
structure and regulation of p53 family activities is
complex. While there may be many redundant activities
among the family members, each p53 family member
also exhibits unique activities and tissue specificity,
particularly in higher organisms. 
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Evolution of p53 family genes 
The p53, p63 and p73 genes evolved from a common
ancestral “p53-like” gene found in simple organisms
such as present-day protostomes (mollusks, Drosophila
and worms, such as C. elegans). FIGURE 1 illustrates
the hypothesized p53 family tree in evolution. While p53
was discovered first, evolutionary conservation of DNA
sequence suggests that p63 arose first during evolution,
then p73 and finally p53. Three extra exons (protein
coding sequences) missing from p53, but found in p63
and p73, code for a sterile alpha motif (SAM) protein
domain, which is thought to be important for protein-
protein interactions. The “p53-like” evolutionary ancestor
contained the SAM domain, but a loss of this domain
occurred in Drosophila and in mammalian p53. During
the process of evolution, a second promoter was
introduced into intron 3 of p63 and p73, providing differ-
ential regulation of a second “start” position for mRNA
and translation at the amino (N) terminus of the protein
to produce isoforms that act as dominant negative
inhibitors (∆N) of the full length, transcriptionally active
(TA) forms [11]. The functions of the various p53 family
members differ along the evolutionary tree. The ances-
tral ∆Np63γ-like isoform found in frogs (Xenopus) is
responsible for both neuroectoderm and ectoderm devel-
opment, while the more recently evolved p73 protein
took on the neuroectoderm development function in
mouse and man, leaving ectodermal formation to p63.
The roles of p63 and p73 in embryonic development
correspond with their primary roles as transcription
factors for regulation of apoptosis. Apoptosis, under strict
spatial and temporal regulation within discrete cells, is
responsible for the sculpting of embryonic tissues.
Synonymous with the function of p53 as a conditional
tumor suppressor that activates upon stress or DNA
damage is the notion that its presence and function
became advantageous to preserve the species as organ-
isms became larger and more complex. The increased
length of time from birth to sexual maturity introduced a
necessity to preserve intact DNA through repair of DNA
damage or induce apoptosis in cells sustaining irrepara-
ble DNA damage. 
p53 family developmental roles
Discovering the roles of the p53 family in human
disease requires genetic, cellular and biochemical analy-
sis of human tissue specimens and astute clinical obser-
vation in addition to researching the gene or its mutant
forms through overexpression or through “knock out” in
mouse or other animal models. Often the best indication
regarding the role of a gene in human disease comes
from discovering the developmental and pathological
effects of deleting the gene in an animal model system.
For example, in mice, deletion of p53 predisposed the
animals to cancers of various organs, while causing no
visible developmental defects. Since p53 is a powerful
tumor suppressor gene, its loss in mice leads to early
demise from the types of cancers (involving tissues such
as blood, muscle and bone) that also develop early in
human patients with Li Fraumeni syndrome, the disease
caused by germ line mutation of human p53. While p53
seems to play little role in embryonic development, p73
is critical for the development of the nervous system [14]
and p63 generated a great deal of excitement in the field
of dermatology for its important role in skin development,
maintenance of stratified squamous epithelium, and
wound repair [15, 16]. FIGURE 2 shows the functional
domains of p63, p73 and p53, and the syndromes known
to date that are associated with mutations in each
functional domain. Mice lacking p63 expression have
severe developmental defects including truncated limbs
and epidermis that lacked stratification and did not
express differentiation markers [16]. Furthermore,
epidermal adnexal structures that also depend upon
epidermal-mesenchymal interactions, such as teeth, hair
follicles, and mammary glands, are absent in p63-
deficient mice. These striking developmental defects in
mice bore resemblance to human developmental disor-
ders with symptoms including combinations and differing
severities of facial abnormalities (thin upper lip or cleft-
ing), failure to separate fingers (ectrodactyly of the hands
and feet, i.e. “lobster claw anomaly”), nasolacrimal duct
obstruction, cleft strands connecting eyelids (i.e.
ankyloblepharon), and cup shaped ears. For these
autosomal dominant disorders; ectrodactyly-ectodermal
dysplasia [17], ankyloblepharon-ectodermal dysplasia
clefting (Hay-Wells Syndrome) [18], acro-dermato-
ungual-lacrimal-tooth (ADULT) syndrome [19], limb-
mammary syndrome [20], Rapp-Hodgkin syndrome [21],
and split hand-split foot malformation syndrome [20], a
thorough genetic analysis of human p63 was performed
and mutant forms of p63 were found in all of them [22]. 
Knock out of p73 genes in mice results in severe
abnormalities of the nervous system and runting (small
animals). p73 is required for normal development of the
hippocampus, a region central to learning and memory
that continues to develop throughout adulthood [23].
Mice lacking p73 exhibit abnormal reproductive and
FIGURE 1
Proposed evolution of the p53 family of genes: Evolutionary conservation of
DNA sequence suggests that TAp63 was the ancestral precursor of the p53
family. Functional specialization among family members evolved as organ-
isms became more complex (see text). A second promoter in intron 3 of p63
and p73 was introduced, producing DN products that act as dominant
negative inhibitors of the full length, transcriptionally active forms. The p53
protein arose as guardian of the genome in higher order organisms with
increased life spans.
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social behavior due to defects in pheromone
detection, attributable to a dysfunction of a nasal
organ that normally expresses high levels of p73.
The tissue specificity of the p73 deficient pheno-
type (concentrated to the brain and related struc-
tures) may be associated with variable patterns of
monoallelic expression in brain, vs. biallelic
expression of p73 in all other tissues [24]. In
studies of mice, neurons in the superior cervical
ganglion (SCG) were depleted by 75% in p73 null
mice compared to littermates expressing the
predominant p73 isoform in brain, ∆Np73. This
dominant negative form inhibited apoptosis in
normal SCG and, of particular note, this apoptosis
appeared to depend upon p53 [25]. To date, there
are no human developmental syndromes associ-
ated with germ line p73 mutations. A systematic
sequencing of p73 genes in familial disorders in
humans, guided by some of the features seen in
the p73 knock-out mice, could elucidate underly-
ing p73 mutations that are likely to be present.
Discerning clinical observation and basic scientif-
ic research cooperated in the discovery that the
striking phenotypes found in animal models of p53
family member deletions (p53 and p63) correlated
with human syndromes.  Thus p53 family
research exemplifies the importance of mouse
models for studying human disease and the value
of continuing dialogue between clinicians and
researchers.
p53 family in epidermal keratinocytes 
Both p63 and p73 are expressed along with
p53 in normal human epidermis and in epidermal
keratinocytes (NHEK) in cell culture. When
NHEKs are induced to differentiate by high
calcium ion exposure in vitro, an isoform of p73
(p73δ) expression increases and all isoforms of
p63 decrease [26]. p73γ, p73δ and p63 trans-
activate the promoters of loricrin and involucrin, two
differentiation-associated molecules critical to epidermal
barrier function, suggesting the involvement of both p63
and p73 in terminal differentiation of keratinocytes.
FIGURE 3A depicts expression of p53 family members
in the epidermis and associated structures. p73 can be
detected in basal cells of the epidermis, columnar basal
cells in hair follicle and peripheral cells and in sebaceous
and meibomian glands [27]. However, p73 has been
associated more with differentiation than with prolifera-
tion. TAp73 isoforms are reported to have roles in differ-
entiation of neuroblastoma (both retinoic acid–induced
and spontaneous) [28], of normal myeloid cells [29], and
in terminal differentiation of human keratinocytes [26].
FIGURE 2
Functional domains of p63, p73 and p53, mouse models, and human
syndromes: Structural similarities between p53 family member proteins
are depicted with protein domain abbreviations as follows: TA,
transactivation domain; ISO, oligomerization/isomerization domain, and
SAM, sterile alpha motif domain (implicated in protein–protein
interactions). Above the structure of each family member protein are
described the developmental defects of mice that are either lacking or
are heterozygous for mutations in the respective p53 family members.
Defects for p63 null mice include severely truncated limbs, skin lacking
stratification and absence of structures that depend upon epidermal-
mesenchymal interactions, such as teeth, hair follicles, and mammary
glands. The null mouse image is reprinted with permission from Nature
Publishing Group [16]. Defects for p73 and p53 mice are noted.
Indicated below the structure of each family member protein are
associated human hereditary disorders linked to specific protein
functional domains. Germ line mutations in human p63 lead to the
following disorders: Acro-dermato-ungual-lacrimal-tooth (ADULT), split
hand-split foot malformation (SHFM), ectrodactyly-ectodermal dysplasia
(EEC), ankyloblepharon-ectodermal dysplasia clefting (AEC - Hay-Wells
Syndrome), limb-mammary syndrome (LMS), and Rapp-Hodgkin
syndrome. Clinical examples of ectrodactyly and mammary gland
hypolasia, phenotypes common to these disorders are shown (reprint
with permission from Elsevier, [58]). As yet, human disorders have not
been linked to germ line p73 mutations. Heterozygous mutations in
germ line p53 lead to Li-Fraumeni syndrome (LFS), a 
predisposition to tumorigenesis. 
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TAp63 isoforms are the first to be expressed during
embryogenesis and initiate epithelial stratification, but
inhibit terminal differentiation, requiring these isoforms to
be counterbalanced with ∆Np63 isoforms to allow skin to
mature [30]. In normal skin, p63 (predominantly truncated
transcriptionally inactive ∆Np63) is expressed in the
nuclei of basal keratinocytes. However, p63 expression
decreases as cells leave the basal layer, withdraw from
the cell cycle, undergo terminal differentiation, and
enlarge to form mature, stratified skin. p63 is also
expressed in the outer root sheath of hair follicles.
Immunohistochemical staining of p63 protein expression
can identify keratinocyte stem cells both in hair follicles
and the basal keratinocyte layer [31].
Analysis of expression of p63 has also
become a useful tool for marking
keratinocytes with increased prolifera-
tive potential, such as in wound
healing and neoplasticity [32]. 
Skin wound healing involves
epidermal regeneration and migration
via hyperproliferation of keratinocytes.
Serial biopsies of human skin healing
taken at time intervals between 2 and
21 days after an injury [33] indicate
that, initially, ∆Np63 mRNA levels are
dramatically decreased in the epider-
mal tongue invading under the scab.
TAp63γ mRNA (the TAp63 isoforms
inhibit terminal differentiation) was
detected in normal mouse skin 30
minutes through 14 days after wound-
ing while TAp63α mRNA levels were
absent immediately following wound-
ing and increased steadily from 3 to 14
days after wounding [34]. FIGURE 3B
graphically depicts relative mRNA
expression levels of tested p63
isoforms during the process of wound
healing. Given that TAp63γ is the most
transcriptionally active isoform of p63, it is
not surprising that this isoform is the first to
be induced following wounding and initially
predominates over ∆Np63 concurrent with
cellular migration and initial reepithelializa-
tion. However, five days after the injury,
∆Np63 mRNA is increased in basal
keratinocytes, associated with normal
keratinocyte differentation, and by day 21,
all p63 isoforms returned to pre-wound
levels, with ∆Np63 predominating. p63
immunostaining is also pronounced in
psoriasis, both in the epidermal rete ridges
of mature lesions and in acanthotic regions
of early lesions, further suggesting p63’s
importance in epithelial proliferation [35].
p53 in cancer – C terminal role in
structure-specific DNA binding
The role of p53 in cancer has been exten-
sively studied since its discovery following
the observation that each tumor-inducing
virus (such as SV40) encodes a protein
dedicated to binding and inactivating wild type p53
protein, emphasizing the central role of p53 in neoplasia
[36].  While all three family members have tumor suppres-
sor roles through transactivation of effector genes, only
p53 has a distinct, second DNA binding domain residing
in the C terminus. This domain is highly charged with
basic amino acids and confers structure-specific DNA
binding, as opposed to sequence-specific DNA binding
like the central DNA binding domain shared among the
p53 family members. Altered DNA structure is observed
after DNA damage, under cellular stress, and at physio-
logical sites of relaxing of double stranded DNA to form
FIGURE 3B
FIGURE 3A
Schematic localization of p53 family member expression in normal skin and p63 expression
during wound healing: 3A) Epidermal structures are depicted summarizing the distribution of
p53 family members in skin layers. p63 is found in the outer root sheath of the hair follicle and
in basal keratinocyte stem cells and can thus function as a marker for stem cell presence. p53
and p73 are expressed in various cell types of the skin, while a delicate balance of p63 isoforms
is crucial for skin development and maintenance. TAp63 is required for initiation of epithelial
stratification, but DNp63 becomes the predominant isoform for maturing skin, promoting
terminal differentiation of keratinocytes. The balance between TAp63 and DNp63 becomes
important during wound healing and disruption of this balance can result in neoplasia.
3B) Graphical representation of relative TAp63 vs. DNp63 mRNA expression during the process of
keratinocyte wound healing: ∆Np63 isoforms decrease within minutes or hours following wounding
while TAp63 isoform expression levels increase (particularly the more transcriptionally active TAp63γ)
during rapid migration and proliferation of new cells. Within 3 days of wounding, ∆Np63 expression
levels increase and both TAp63 and ∆Np63 levels remain increased from day 7 to day 14.
Subsequently, TAp63 expression levels decrease and ∆Np63 resumes its role in promoting terminal
differentiation for maintenance of mature skin. By day 21 all isoforms return to their pre-wound
levels.
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single-stranded DNA, such as during transcription or at
telomeres, i.e. ends of chromosomes. This facet of p53’s
DNA binding character illustrates its importance to
responding to DNA damage. Recently our laboratory has
shown that the C terminus of full length p53 confers rapid
binding to DNA through its non-sequence specific
binding ability, facilitating the search for and activation of
specific growth arrest genes following genotoxic stress.
This protects the DNA by halting replication until the
completion of DNA repair, a function lost in p53 mutants
that lack the C terminal structure-specific domain [37].
Without this activity, cells would be subject to increased
mutation rates and increased cancer risk. The p63 and
p73 family members lack this rapid response module,
consistent with their focus of activities on apoptosis in
cells sustaining irreparable damage. 
p63 and p73 in squamous cell carcinoma,
basal cell carcinoma, and melanoma
p63 or p73 knock-out mice did not develop cancer as
early as p53 null mice. However, p63 or p73 heterozy-
gous mice did develop tumors predominately of epithelial
origin (including SCC) at a rate higher than wild-type
mice [38]. Moreover, mice heterozygous for combin-
ations of family member genes (i.e. p63+/-;p73+/-, p53+/-
;p73+/-, and p53+/-;p63+/-) had multiple tumors and
more rapidly metastasizing tumors than mice deficient
for p53 alone. p73 is found expressed in basal cell carci-
nomas (BCC) and in basal cells in seborrheic keratosis.
While the mechanisms underlying the roles of p63 and
p73 in tumor suppression are not yet fully defined, their
roles in homeostasis, differentiation and proliferation are
indicative of tumor suppressive function. It has been
shown that the relationship between p63 and p73 and
epithelial carcinogenesis in null mice is consistent with
models of sporadic cancer progression to SCC in
keratinocyte lineages [39] and with many human tumors
that also have reduced expression of p63 and p73 [40-
45]. While deficiency of these proteins has been charac-
terized in some tumors, overexpression of p63 and p73
isoforms has been found in others [46]. In well-differenti-
ated human SCC, p63 is readily detected in the cell
nuclei while less differentiated tumors frequently show
further increase in p63 expression, correlating with a
higher fraction of rapidly dividing cells. It seems that both
TA and ∆Np63 isoforms can have oncogenic potential
[47, 48]. These findings can be unified by understanding
that a balance among p63 isoforms and between p63
and other p53 family proteins, and defects in other gene
functions are crucial in determining the development of
SCC and other epithelial cancers [38]. 
In order to begin to explain isoform-specific activities
in tumor suppression, we have taken a global view of all
three family members’ expression and activities in
mouse keratinocyte and melanocyte lineages during
carcinogenesis [39]. We examined the total levels of
each isoform, their ability to bind to DNA promoters of
growth arrest and apoptosis genes, and the induction of
downstream effector genes for growth arrest or apopto-
sis in response to DNA damage signals, i.e. ionizing
radiation (IR) and sunlight (UVB). The coordination of
biochemical events with outcomes in the cell enables
identification of unique or cooperative mechanisms of the
p53 family members. 
p53, p63 and p73 isoforms are expressed and differ-
entially active at different stages of carcinogenesis, both
in vivo and in cell culture models of mouse epidermal
keratinocytes [49] and melanocytes [52]. TABLE 1
summarizes p53 family member expression and
activities in human and mouse SCC and melanoma.
Mouse keratinocytes in culture expressed multiple
isoforms each of p73 and p63. Interestingly, these cells
expressed the TA isoforms typical of healing wound
epidermis, as well as the ∆N isoforms that predominate
in intact epidermis [33, 34]. The p73 and p63 isoforms
bound p21 and apoptosis-associated noxa DNA probes
after IR or UVB treatment, correlating with p21 and noxa
mRNA induction and with cell cycle arrest and apoptosis.
In non-transformed keratinocytes we found downregulat-
ed p73 (TAα and ∆Nα) DNA binding after IR or UVB
treatment, coupled with increased p63 and p53 binding
to p21 and noxa probe sequences. The reduction in p73
DNA binding correlated with growth arrest and reduced
viability in colony forming assays. In initiated
keratinocytes, p73 DNA binding remained high after
treatment, correlating neoplasia with prolonged p73
competition against p63 and p53 for these promoter
sites. However, a striking loss of p73 protein expression
occurred at malignant conversion to SCC, with con-
comitant loss of target DNA binding by lower molecular
weight p63 isoforms (TAβ and TAγ). These findings
correlate regulated p73 DNA binding with recruitment of
transactivating p63 isoforms after IR in non-transformed
cells, and p73 deficiency with defects in p63 and p53
TABLE 1
Mouse model systems for SCC and melanoma summarizing p53 family
member expression and activity: Expressions of total p53 family members,
DNA binding, and transcriptional and cellular outcomes following DNA
damage are summarized for a clonal keratinocyte model [49] and a
melanocyte [52] carcinogenesis model. See text for detail, modified 
from JID supplement in press, Montagna Symposium 2004 [39].
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activities and with malignant conversion [39 and
unpublished data]. 
p53 family in epidermal melanocytes 
and melanoma
Analysis of melanoma development and progression
reveals increased expression of ∆Np73 isoforms [12].
While human melanomas rarely carry p53 genetic
mutations, at least 50% of wild type p53 protein function
is retained in the majority of mutations that do occur [50].
Investigation of melanocytic nevi, primary melanoma,
and metastatic melanoma tissues revealed that
increased expression of p73 was associated with the
progression from primary melanoma to metastatic
disease [51]. Two N terminal splice variants of TAp73
(p73∆ex2 and p73∆ex2/3 which lack exons 2 and/or 3
found in full length TAp73) were also found to be
increased in melanoma and this correlated with
aberrantly high levels of TAp73 and E2F1 [12]. E2F1 is
a cell cycle regulator known to transactivate expression
of p73, but E2F1’s role in controlling progression to
metastatic melanoma remains to be verified. 
In contrast to the expression of the broad spectrum of
p63 and p73 isoforms in cultured keratinocytes, evalua-
tion of a melanocyte carcinogenesis model [52] revealed
more restricted isoform expression, consisting of
∆Np73α, two p63 isoforms (putative TAp63β and
possibly TAp63γ or ∆Np63β) and p53. Although p21 and
noxa mRNA levels increased following DNA damage in
non-transformed melanocytes, p53 family member
binding to p21 and noxa DNA probes was undetectable.
Interestingly, IR-resistant malignant melanocytes and
keratinocytes both exhibited noxa mRNA induction after
UVB treatment, but this noxa induction only correlated
with DNA binding of p53 family proteins to the noxa
probe in keratinocytes, not in melanocytes. These
results suggest p53 family-independent responses to
DNA damage in melanocytes, attributable to other
transcription factors. More detailed studies of responses
to IR, to UVB, and of DNA binding of p53 family
members in vivo correlated with biological differences in
outcomes of apoptosis and cell cycle arrest is needed to
fill the remaining gaps in knowledge, particularly of
melanocytes and melanoma.
p53 family member defects are insufficient for
conversion to cancer
It is important to emphasize that multiple genetic
events within the same progenitor cell are required for
progression to cancer, as observations of carcinogene-
sis in animal models and humans consistently demon-
strate. Mutations or defective function of wild type p53
family member proteins require further events, either
induced or spontaneous, prior to malignant conversion.
Supporting this concept, biopsy from normal appearing
human skin has revealed clusters of keratinocytes with
mutated p53. By escaping terminal differentiation and
sloughing, these cells are extending the window for
sustaining other events that cause progression of skin
tumor development. Cancer progression occurs through
genetic changes caused by DNA damaging agents such
as irradiation or antiproliferative DNA analogues (e.g. 5
fluorouracil), coupled with selection of initiated cells by
repeated exposure to agents that drive tissue turnover,
such as sunlight, tumor promoters such as retinoic acid,
or even wound healing. If sensitive to the particular
agent, the p53 mutant cells will fail to survive; if resistant,
a selective growth advantage may allow cells with
mutant p53 to increase in number relative to surrounding
normal keratinocytes. Given the observation that mice
lacking p63, p73 or both are increasingly prone to multi-
ple cancers and metastatic cancers, investigation of the
role of all the p53 family members in SCC and other
cancers is warranted in the attempt to uncover the basis
for aggressive SCC progression. 
We are interested in uncovering other malignancy-
specific events that may accompany alterations in p53
family activities. Melanocytes and keratinocytes are
being analyzed for malignancy-specific gene expression
changes in the etiology of multi-step cancer. One
approach is to use gene expression information from the
mouse clonal lineage models (representing early
through late cancer progression stages) to inform which
genes are potentially causal events in human cancers.
We queried microarray data for early gene expression
changes that were exacerbated in malignant derivatives
and also differentially expressed in human advanced
melanoma vs. normal melanocytes [39]. Using a novel
method for ranking and normalization of microarray data
for five thousand probe sets, 27 upregulated and 13
downregulated genes satisfied our query. Of these, the
majority associated with late stage human cancers and
six were novel genes. Determining other events that
predict high risk for relapse after surgical intervention will
be crucial for early detection, and for prognosis of which
SCC or melanomas are likely to recur after surgery,
requiring adjuvant treatment optimization.
p53 family in drug therapy and resistance
The growing knowledge of p63 and p73 functions in
skin and of p53 as an important mediator of response to
drug treatments will have impact upon how dermatolog-
ic diseases are treated and how skin products are devel-
oped. For example, in the cancer field, if overexpression
of p73 is determined to be important in BCC progression,
as noted above, it may be a new target for therapy or
prevention. One recent study showed that p73 is a target
of the retinoid tazarotene, thereby suggesting a growth
inhibiting treatment of skin tumors with high levels of p73
[53]. The TAp73 (p73∆ex2 and p73∆ex2/3) variants
found to be overexpressed in metastatic melanoma are
known dominant negative inhibitors of p53 [54]. This
provides a potential mechanism for melanoma progres-
sion even though most melanomas retain wild type p53.
The importance of p53 and p73 pathways in melanoma
is suggested by findings that oligonucleotides homolo-
gous to the telomere 3' overhang sequence (T-oligo) in
tumors from human melanoma cell lines induce apopto-
sis through p53 and p73 [55]. Targeted manipulation of
the p53 family through use of agents such as tazarotene
or T-oligo could provide novel therapeutics for
melanoma.
In addition to directed p53 family protein activation for
therapeutic effect, temporary downregulation of p53
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